These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 8786246)

  • 21. Development of Sang-35: a cyclosporine formulation bioequivalent to Neoral.
    First MR; Alloway R; Schroeder TJ
    Clin Transplant; 1998 Dec; 12(6):518-24. PubMed ID: 9850444
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Abbreviated pharmacokinetic profiles in area-under-the-curve monitoring of cyclosporine therapy in de novo renal transplant patients treated with Sandimmune or Neoral. Neoral study group.
    Marsh CL
    Ther Drug Monit; 1999 Feb; 21(1):27-34. PubMed ID: 10051051
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclosporine bioavailability of Neoral and Sandimmune in white and black de novo renal transplant recipients. Neoral Study Group.
    Pollak R; Wong RL; Chang CT
    Ther Drug Monit; 1999 Dec; 21(6):661-3. PubMed ID: 10604829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cyclosporine bioequivalence study: quantification using fluorescence polarization immunoassay (FPIA) and radioimmunoassay (RIA).
    Mendes GD; de Oliveira CH; Sucupira M; Donato JL; Moreno RA; De Nucci G
    Int J Clin Pharmacol Ther; 2004 Feb; 42(2):125-32. PubMed ID: 15180174
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Conversion of psoriasis patients from the conventional formulation of cyclosporin A to a new microemulsion formulation: a randomized, open, multicentre assessment of safety and tolerability.
    Zachariae H; Abrams B; Bleehen SS; Bräutigam M; Burrows D; Ettelt MJ; Fry L; Happle R; Haustein UF; Ganslandt J; Jung EG; Knop J; Kühne KH; Mellein B; Mørk NJ; Rogers S; Schmidt AG; Schopf RE; Sumner M; Taube KM; Weidinger G; Wurdel C; Zahn E
    Dermatology; 1998; 196(2):231-6. PubMed ID: 9568413
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy of Neoral in the immediate postoperative period in children post-liver transplantation.
    van Mourik ID; Melendez HV; Thomson M; Mieli-Vergani G; Heaton N; Kelly DA
    Liver Transpl Surg; 1998 Nov; 4(6):491-8. PubMed ID: 9791160
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A bioavailability study of cyclosporine: comparison of Neoral versus Cysporin in stable heart transplant recipients.
    Leet A; Richardson M; Senior JA; Funston R; Skiba M; Bailey M; Krum H
    J Heart Lung Transplant; 2009 Sep; 28(9):894-8. PubMed ID: 19716041
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A limited sampling strategy for the estimation of 12-hour SangCya and neoral AUCs in renal transplant recipients.
    Meier-Kriesche HU; Alloway R; Gaber AO; Canafax DM; Kaplan B
    J Clin Pharmacol; 1999 Feb; 39(2):166-71. PubMed ID: 11563409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of neoral and sandimmune for liver transplantation (NOF-8).
    Grant D; Kneteman N; Tchervenkov J; Roy A; Murphy G; Tan A; Hendricks L; Guilbault N; Levy G
    Transplantation; 1999 Apr; 67(8):1133-7. PubMed ID: 10232563
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A meta-analysis to assess the safety and tolerability of two formulations of cyclosporine: Sandimmune and Neoral.
    Shah MB; Martin JE; Schroeder TJ; First MR
    Transplant Proc; 1998 Dec; 30(8):4048-53. PubMed ID: 9865291
    [No Abstract]   [Full Text] [Related]  

  • 31. NOF-11: a one-year pediatric randomized double-blind comparison of neoral versus sandimmune in orthotopic liver transplantation.
    Alvarez F; Atkison PR; Grant DR; Guilbault N; Jones AB; Kim PS; Kneteman NM; Laurin L; Martin SR; Murphy GF; Paradis K; Shapiro J; Smith LJ; Superina RA
    Transplantation; 2000 Jan; 69(1):87-92. PubMed ID: 10653385
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Consistent absorption of cyclosporine from a microemulsion formulation assessed in stable renal transplant recipients over a one-year study period.
    Wahlberg J; Wilczek HE; Fauchald P; Nordal KP; Heaf JG; Olgaard K; Hansen JM; Lokkegaard H; Mueller EA; Kovarik JM
    Transplantation; 1995 Oct; 60(7):648-52. PubMed ID: 7570970
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The evaluation of the safety and tolerability of two formulations of cyclosporine: neoral and sandimmune. A meta-analysis.
    Shah MB; Martin JE; Schroeder TJ; First MR
    Transplantation; 1999 Jun; 67(11):1411-7. PubMed ID: 10385078
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conversion from Sandimmune to Neoral in organ transplant recipients.
    Bartucci MR; Bayer L; Brooks BK; Chandler L; Himes V; Meiergerd D; Newby B; Satmary NT; Shieck V
    J Transpl Coord; 1998 Dec; 8(4):227-33; quiz 234-5. PubMed ID: 10205463
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation.
    Mueller EA; Kovarik JM; van Bree JB; Tetzloff W; Grevel J; Kutz K
    Pharm Res; 1994 Feb; 11(2):301-4. PubMed ID: 8165192
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reversal of cyclosporine malabsorption in diabetic recipients of simultaneous pancreas and kidney transplant using a microemulsion formulation.
    Chapman JR; O'Connell PJ; Bovington KJ; Allen RD
    Transplantation; 1996 Jun; 61(12):1699-704. PubMed ID: 8685946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery.
    Banner NR; David OJ; Leaver N; Davis J; Breen J; Johnston A; Yacoub MH
    Transpl Int; 2002 Dec; 15(12):649-54. PubMed ID: 12478413
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differences in bioavailability between oral cyclosporine formulations in maintenance renal transplant patients.
    Curtis JJ; Barbeito R; Pirsch J; Lewis RM; Van Buren DH; Choudhury S
    Am J Kidney Dis; 1999 Nov; 34(5):869-74. PubMed ID: 10561143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concurrent administration of water-soluble vitamin E can increase the oral bioavailability of cyclosporine a in healthy dogs.
    Fischer JR; Harkin KR; Freeman LC
    Vet Ther; 2002; 3(4):465-73. PubMed ID: 12584684
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetic profile and variability of cyclosporine versus neoral in patients with cystic fibrosis after lung transplantation.
    Kesten S; Scavuzzo M; Chaparro C; Szalai JP
    Pharmacotherapy; 1998; 18(4):847-50. PubMed ID: 9692659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.